Literature DB >> 8557989

Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells.

J Norgauer1, B Metzner, I Schraufstätter.   

Abstract

The chemokine GRO alpha is an autocrine growth factor for melanoma cells. Although GRO alpha has been identified as a high affinity ligand for the IL-8 receptor beta (IL-8R beta) in recombinant systems, the receptor mediating its action in melanoma cells has been a matter of debate. Here, we show by reverse transcription and PCR expression of IL-8R beta, mRNA transcripts in different melanoma cell lines and in normal human melanocytes. To characterize the role of the IL-8R beta in melanoma cells, antiserum was raised in rabbits against a fusion protein containing the NH2-terminal portion of the receptor. Its specificity was shown by flow cytometry with IL-8R beta-transfected HL60 cells. A specific epitope could be mapped with IL-8R beta mutants to the peptide sequence between ASP-4 and ASP-14 of this receptor. Binding studies with [125I]GRO alpha in IL-8R beta transfectants indicated ligand antagonistic properties of this Ab. Expression of IL-8R beta protein at the cell surface of various melanoma cell lines could be shown by flow cytometry with F(ab')2 fragments of the IL-8R beta antiserum. Moreover, anti-IL-8R beta Ab partially blocked specific binding of [125I]GRO alpha in various melanoma cell lines. Addition of F(ab')2 fragments of the IL-8R beta antiserum or of neutralizing anti-GRO alpha mAb to different melanoma cell lines identified this GRO alpha-IL-8R beta interaction as a major component required for serum-independent melanoma cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557989

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.

Authors:  M Nees; J M Geoghegan; T Hyman; S Frank; L Miller; C D Woodworth
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Chemokines--linking receptors to response.

Authors:  Malcolm L Watson
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 3.  Role of TLR2-dependent inflammation in metastatic progression.

Authors:  Sunhwa Kim; Michael Karin
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

4.  The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma.

Authors:  H Haghnegahdar; J Du; D Wang; R M Strieter; M D Burdick; L B Nanney; N Cardwell; J Luan; R Shattuck-Brandt; A Richmond
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

5.  Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Authors:  T Botton; A Puissant; Y Cheli; T Tomic; S Giuliano; L Fajas; M Deckert; J-P Ortonne; C Bertolotto; S Tartare-Deckert; R Ballotti; S Rocchi
Journal:  Cell Death Differ       Date:  2010-07-02       Impact factor: 15.828

6.  Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm.

Authors:  Philip Y Wai; Paul C Kuo
Journal:  World J Clin Oncol       Date:  2012-02-10

Review 7.  CXCL8 and its cognate receptors in melanoma progression and metastasis.

Authors:  Seema Singh; Ajay P Singh; Bhawna Sharma; Laurie B Owen; Rakesh K Singh
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

8.  A synthetic peptide inhibitor for alpha-chemokines inhibits the growth of melanoma cell lines.

Authors:  S Hayashi; A Kurdowska; A B Cohen; M D Stevens; N Fujisawa; E J Miller
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 9.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

Review 10.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.